88 Patients, 0 Intubated: Israeli ‘Precision’ COVID Drug Wraps Up Early Trial

This article was first published by The Times of Israel and is re-posted with permission.

The Israeli inventor of a “precision medicine” for COVID-19 is “very optimistic,” after an 88-person hospital trial entered its final day without a single patient ending up on a ventilator. The next phase of the drug trial will see a trial performed with some in a group given a placebo.

SEE ALSO: Israeli COVID-19 Vaccine In Pill Form To Start Clinical Trial In Tel Aviv

After a first trial in Israel, this trial, which will wrap up on Tuesday [last week], is taking place in Greece, sponsored by the government in Athens, involving moderate and serious patients aged up to 85. Almost 90 percent of them were released within five days, although some remain hospitalized.

The patients were given the inhaled drug EXO-CD24, developed at Tel Aviv’s Ichilov Medical Center.

To read the full article, click here.